Rhenman & Partners Asset Management AB Lowers Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Rhenman & Partners Asset Management AB cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 16.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,000 shares of the company’s stock after selling 7,270 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in TransMedics Group were worth $2,369,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in TMDX. Clear Creek Financial Management LLC acquired a new stake in TransMedics Group in the 4th quarter valued at $352,000. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares during the period. Baillie Gifford & Co. lifted its holdings in TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $6,734,000. Finally, Zacks Investment Management purchased a new stake in shares of TransMedics Group during the third quarter worth about $1,607,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Down 4.6 %

NASDAQ TMDX opened at $67.67 on Friday. The business’s fifty day simple moving average is $70.07 and its 200-day simple moving average is $85.74. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37.

Analysts Set New Price Targets

TMDX has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Piper Sandler decreased their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.